CSL Of Australia, Talecris Of U.S. Warned By FDA Over Plasma Promos
This article was originally published in PharmAsia News
Executive SummaryAustralia's CSL has been accused, along with U.S.-based Talecris, of making misleading claims in competing promotion campaigns for blood products
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.